Skip to main content
. Author manuscript; available in PMC: 2018 Apr 3.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2016 Dec 21;98(4):900–907. doi: 10.1016/j.ijrobp.2016.12.022

Fig. 1.

Fig. 1

Kaplan-Meier estimates of progression-free survival (PFS; panel A) and overall survival (OS) (panel B) according to age <75 or ≥75 years at stereotactic ablative radiotherapy (SABR). No difference was found in PFS (P=0.475) or in OS for the first 2 years after treatment, is the same up to 2 years after treatment, but differences in OS according to age became apparent after that time (P=0.003). OS was also found to decrease as a function of age in a secondary univariate analysis (panel C, P=0.001).